Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 4 institutions in 1 country.
Yuchen WangBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.ORCID 0009-0005-5060-4245
Xi GuoTEDA Institute of Biological Sciences and Biotechnology, Nankai University, Tianjing 300457, China.
Xinran ZhangBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.ORCID 0009-0000-8030-4490
Ping ChenDivision of Dermatology and Mycological Lab, Peking University Third Hospital, Beijing 100191, China.
Wenhui WangDivision of Dermatology and Mycological Lab, Peking University Third Hospital, Beijing 100191, China.
Shan HuBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.
Teng MaBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.
Xingchen ZhouBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.
Dongming LiDivision of Dermatology and Mycological Lab, Peking University Third Hospital, Beijing 100191, China.
Ying YangBioinformatics Center of AMMS, Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing Institute of Microbiology and Epidemiology, Beijing 100850, China.
Institute of Microbiology · CNPeking University · CNChina Pharmaceutical University · CNNankai University · CN
Funding
Ministry of Science and Technology 2018ZX10101003 2018ZX10712001National Key Research and Development Program of China 2018YFB2001204National Natural Science Foundation of China 51771226National Natural Science Foundation of China 81871734 81471994 32070019 32270002
6 · The paper itself
Abstract
Ten
Indexed as
candidiasisfungigeneticsmicroevolutionrhinofacial and rhino–orbital–cerebral mycosis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In Vivo Microevolutionary Analysis of a Fatal Case of Rhinofacial and Disseminated Mycosis Due to Azole-Drug-Resistant Candida Species. · full record | OpenQuestion